Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of the malaria parasite

Goulielmaki, E., Kaforou, S., Venugopal, K. , Loukeris, T. G., Siden-Kiamos, I. and Koussis, K. (2018) Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of the malaria parasite. Molecular and Biochemical Parasitology, 220, pp. 10-14. (doi: 10.1016/j.molbiopara.2017.12.003) (PMID:29305880)

169758.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



In an effort to eradicate malaria, new interventions are proposed to include compound/vaccine development against pre-erythrocytic, erythrocytic and mosquito stages of Plasmodium. Drug repurposing might be an alternative approach to new antimalarials reducing the cost and the time required for drug development. Previous in vitro studies have examined the effects of protease inhibitors on different stages of the Plasmodium parasite, although the clinical relevance of this remains unclear. In this study we tested the putative effect of three HIV protease inhibitors, two general aspartyl protease inhibitors and three AAA-p97 ATPase inhibitors on the zygote to ookinete transition of the Plasmodium parasite. Apart from the two general aspartyl inhibitors, all other compounds had a profound effect on the development of the parasites. HIVPIs inhibited zygote to ookinete conversion by 75%–90%, while the three AAA-p97 ATPase inhibitors blocked conversion by 50%–90% at similar concentrations, while electron microscopy highlighted nuclear and structural abnormalities. Our results highlight a potential of HIV protease inhibitors and p97 inhibitors as transmission blocking agents for the eradication of malaria.

Item Type:Articles
Additional Information:The work was supported by the grant Transmalaria bloc (contract number GA223736) to T.G.L. Konstantinos Koussis was supported by the Action “Supporting Postdoctoral Researchers” of the Operation Program “Education and Lifelong Learning” (Action’s Beneficiary: General Secretariat for Research and Technology), and is co-financed by the European Social Fund (ESF) and the Greek State.
Glasgow Author(s) Enlighten ID:Venugopal, Dr Kannan
Authors: Goulielmaki, E., Kaforou, S., Venugopal, K., Loukeris, T. G., Siden-Kiamos, I., and Koussis, K.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Molecular and Biochemical Parasitology
ISSN (Online):1872-9428
Published Online:03 January 2018
Copyright Holders:Copyright © 2017 Elsevier B.V.
First Published:First published in Molecular and Biochemical Parasitology 220: 10-14
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record